{
    "organizations": [],
    "uuid": "f4a74b5350b5981478f9eef98bd046625570a69e",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/27/globe-newswire-beyondspring-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-on-april-3-2018.html",
    "ord_in_thread": 0,
    "title": "BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial results on Tuesday, April 3, 2018. BeyondSpring’s management team will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, April 3, 2018, to discuss the financial results and provide an operational update.\nThe conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 3765248. A live webcast will be available on the Investors page of the Company's website at http://ir.beyondspringpharma.com . An archived replay of the webcast will be available for 30 days.\nAbout BeyondSpring\nBeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.\nContact:\nInvestor Relations:\nLaura Perry or Joe Rayne\nArgot Partners\n212.600.1902\nBeyondSpring@argotpartners.com\nSource:BeyondSpring, Inc.",
    "published": "2018-03-28T00:05:00.000+03:00",
    "crawled": "2018-03-28T04:58:05.032+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "new",
        "york",
        "march",
        "globe",
        "newswire",
        "beyondspring",
        "nasdaq",
        "bysi",
        "global",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "transformative",
        "cancer",
        "therapy",
        "today",
        "announced",
        "company",
        "report",
        "financial",
        "result",
        "tuesday",
        "april",
        "beyondspring",
        "management",
        "team",
        "host",
        "conference",
        "call",
        "webcast",
        "eastern",
        "time",
        "tuesday",
        "april",
        "discus",
        "financial",
        "result",
        "provide",
        "operational",
        "update",
        "conference",
        "call",
        "may",
        "accessed",
        "dialing",
        "international",
        "referencing",
        "conference",
        "id",
        "live",
        "webcast",
        "available",
        "investor",
        "page",
        "company",
        "website",
        "http",
        "archived",
        "replay",
        "webcast",
        "available",
        "day",
        "beyondspring",
        "beyondspring",
        "global",
        "biopharmaceutical",
        "company",
        "developing",
        "innovative",
        "cancer",
        "therapy",
        "robust",
        "pipeline",
        "internal",
        "development",
        "collaboration",
        "university",
        "washington",
        "de",
        "novo",
        "drug",
        "discovery",
        "using",
        "ubiquitination",
        "platform",
        "beyondspring",
        "lead",
        "asset",
        "plinabulin",
        "phase",
        "clinical",
        "trial",
        "direct",
        "anticancer",
        "agent",
        "cell",
        "lung",
        "cancer",
        "study",
        "two",
        "phase",
        "clinical",
        "program",
        "prevention",
        "neutropenia",
        "cin",
        "study",
        "beyondspring",
        "seasoned",
        "management",
        "team",
        "many",
        "year",
        "experience",
        "bringing",
        "drug",
        "market",
        "contact",
        "investor",
        "relation",
        "laura",
        "perry",
        "joe",
        "rayne",
        "argot",
        "partner",
        "beyondspring",
        "source",
        "beyondspring",
        "inc"
    ]
}